David Orr

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients

Edward Gane, Frank Weilert, David Orr et al. · Liver International · 2010 · 375 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar et al. · Journal of Hepatology · 2023 · 192 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation

Anna Dare, Lindsay D. Plank, Anthony R. J. Phillips et al. · Liver Transplantation · 2014 · 104 citations · Full text

Medicine, Endocrinology, Cardiac Transplantation +16